Scalper1 News
Amgen (AMGN) and Regeneron Pharmaceuticals (REGN) were both up Tuesday on upgrades from UBS after a survey suggested sales of their new cholesterol drugs could be even bigger than expected. Analyst Matthew Roden raised his rating on Regeneron all the way to buy from sell, and on Amgen to buy from neutral, after surveying 50 U.S. and European physicians about their attitudes toward the new PCSK9 inhibitors both companies have launched this summer. Scalper1 News
Scalper1 News